ALTEOGEN Inc.

KOSDAQ:A196170 Stock Report

Market Cap: ₩15.6t

ALTEOGEN Valuation

Is A196170 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A196170 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A196170 (₩292000) is trading below our estimate of fair value (₩791244.6)

Significantly Below Fair Value: A196170 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A196170?

Key metric: As A196170 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A196170. This is calculated by dividing A196170's market cap by their current book value.
What is A196170's PB Ratio?
PB Ratio83.8x
Book₩185.73b
Market Cap₩15.56t

Price to Book Ratio vs Peers

How does A196170's PB Ratio compare to its peers?

The above table shows the PB ratio for A196170 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average7.9x
A068270 Celltrion
2.1x73.6%₩35.8t
A145020 Hugel
3.8x20.7%₩3.0t
A214450 PharmaResearch
4.3x25.3%₩2.1t
A007390 NatureCellLtd
21.3xn/a₩1.4t
A196170 ALTEOGEN
83.8x94.1%₩15.6t

Price-To-Book vs Peers: A196170 is expensive based on its Price-To-Book Ratio (83.8x) compared to the peer average (7.9x).

Price to Book Ratio vs Industry

How does A196170's PB Ratio compare vs other companies in the KR Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
A377740 BioNote
0.3xn/aUS$334.25m
A109960 AP Healthcare
0.3xn/aUS$67.90m
No more companies available in this PB range
A196170 83.8xIndustry Avg. 2.5xNo. of Companies11PB01.63.24.86.48+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: A196170 is expensive based on its Price-To-Book Ratio (83.8x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A196170's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A196170 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio83.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A196170's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A196170 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩292,000.00
₩390,000.00
+33.6%
63.9%₩730,000.00₩140,000.00n/a3
Nov ’25₩356,500.00
₩271,666.67
-23.8%
36.1%₩375,000.00₩140,000.00n/a3
Oct ’25₩327,000.00
₩271,666.67
-16.9%
36.1%₩375,000.00₩140,000.00n/a3
Sep ’25₩319,000.00
₩271,666.67
-14.8%
36.1%₩375,000.00₩140,000.00n/a3
Aug ’25₩319,000.00
₩271,666.67
-14.8%
36.1%₩375,000.00₩140,000.00n/a3
Jul ’25₩277,500.00
₩246,666.67
-11.1%
30.6%₩300,000.00₩140,000.00n/a3
Jun ’25₩185,900.00
₩201,250.00
+8.3%
50.8%₩300,000.00₩65,000.00n/a4
May ’25₩176,900.00
₩168,333.33
-4.8%
58.2%₩300,000.00₩65,000.00n/a3
Apr ’25₩186,300.00
₩168,333.33
-9.6%
58.2%₩300,000.00₩65,000.00n/a3
Mar ’25₩160,600.00
₩168,333.33
+4.8%
58.2%₩300,000.00₩65,000.00n/a3
Feb ’25₩71,400.00
₩90,000.00
+26.1%
22.7%₩115,000.00₩65,000.00n/a3
Jan ’25₩98,500.00
₩83,333.33
-15.4%
27.0%₩115,000.00₩65,000.00n/a3
Dec ’24₩82,600.00
₩83,333.33
+0.9%
27.0%₩115,000.00₩65,000.00n/a3
Nov ’24₩62,800.00
₩83,333.33
+32.7%
27.0%₩115,000.00₩65,000.00₩356,500.003
Oct ’24₩68,100.00
₩83,333.33
+22.4%
27.0%₩115,000.00₩65,000.00₩327,000.003
Sep ’24₩43,750.00
₩70,000.00
+60.0%
5.8%₩75,000.00₩65,000.00₩319,000.003
Aug ’24₩44,050.00
₩70,000.00
+58.9%
5.8%₩75,000.00₩65,000.00₩319,000.003
Jul ’24₩42,950.00
₩70,000.00
+63.0%
5.8%₩75,000.00₩65,000.00₩277,500.003
Jun ’24₩52,800.00
₩70,000.00
+32.6%
5.8%₩75,000.00₩65,000.00₩185,900.003
May ’24₩43,500.00
₩70,000.00
+60.9%
5.8%₩75,000.00₩65,000.00₩176,900.003
Apr ’24₩39,650.00
₩70,000.00
+76.5%
7.1%₩75,000.00₩65,000.00₩186,300.002
Mar ’24₩37,650.00
₩62,666.67
+66.4%
17.8%₩75,000.00₩48,000.00₩160,600.003
Feb ’24₩38,050.00
₩62,666.67
+64.7%
17.8%₩75,000.00₩48,000.00₩71,400.003
Jan ’24₩38,250.00
₩68,000.00
+77.8%
4.4%₩71,000.00₩65,000.00₩98,500.002
Dec ’23₩38,350.00
₩67,916.67
+77.1%
4.3%₩70,833.33₩65,000.00₩82,600.002
Nov ’23₩35,850.00
₩70,000.00
+95.3%
1.2%₩70,833.33₩69,166.67₩62,800.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Bioneer

₩513.9b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

7D

-0.7%

1Y

-34.6%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

7D

-4.8%

1Y

n/a

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩128,800.00

7D

2.1%

1Y

-41.2%